Last updated: February 3, 2026
What is the current investment landscape for the ACTH drug?
The pharmaceutical market for adrenocorticotropic hormone (ACTH) primarily involves the treatment of infantile spasms, multiple sclerosis, and other inflammatory conditions. The market has experienced volatility due to patent expirations, regulatory challenges, and the emergence of biosimilars.
The only FDA-approved synthetic ACTH product, Acthar Gel, is produced by Mallinckrodt Pharmaceuticals. Its market value reached approximately $430 million in 2021, according to IQVIA data. The product's patent expiration in 2023 has prompted interest in biosimilars and alternative therapies.
Five pharmaceuticals are actively developing or marketing ACTH formulations:
- Mallinckrodt (Acthar Gel)
- Novartis (discontinued plans for biosimilar)
- Teva (biosimilar candidates)
- Sandoz (biosimilar development)
- Adamis (research-stage ACTH analogs)
Investment interest hinges on regulatory approvals, patent disputes, biosimilar entry, and pricing dynamics. Institutional investors are cautious, given the product's high prices, regulatory risks, and competition.
What are the key fundamentals affecting ACTH drug investments?
Market Size and Growth
- Global Market: Estimated at $400–$500 million (2021), with growth driven by indications like infantile spasms and multiple sclerosis.
- Growth Rate: Compound annual growth rate (CAGR) projected at 5–7% through 2025, driven by increasing diagnosis rates and expanding indications.
Revenue Drivers
- Pricing: Acthar Gel retails at approximately $38,000 per vial. High reimbursement rates sustain revenue but invite biosimilar competition.
- Volume: Prescriptions for infantile spasms drive core volume. Off-label use in multiple sclerosis and nephrotic syndrome influences total sales.
Patent and Regulatory Status
- Patent Expiry: The last patent expired in 2023, exposing the product to biosimilar competition.
- Regulatory Hurdles: Biosimilar approval pathways are complex; biosimilars must demonstrate high similarity to Acthar Gel, which has a broad immunogenic profile complicating approval.
Competitive Dynamics
- Biosimilars: Sandoz and Teva are developing biosimilars; approval could erode margins.
- Pricing Trends: Payers and regulators scrutinize high drug prices; recent pressure could lead to discounts or formulary exclusions.
R&D and Pipeline Status
- No significant pipeline products targeting ACTH are in late-stage development. Most efforts are focused on biosimilar entry.
Political and Policy Factors
- Department of Justice investigations into pricing practices impact market sentiment.
- Regulatory push for biosimilars and cost-containment influences future pricing and commercialization.
Risks
- Patent litigation and biosimilar approval delays.
- Regulatory scrutiny and potential price regulation.
- Market acceptance of biosimilars and off-label uses.
How do diverse market conditions influence investment fundamentals?
| Criterion |
Impact |
Data |
| Market size |
Limited but steady growth, capped by biosimilar entry |
$400–$500 million (2021), CAGR 5–7% |
| Patent expiration |
Induces risk of biosimilar competition |
Last patent expired in 2023 |
| Regulatory environment |
Complex approval pathways for biosimilars |
Biosimilars must demonstrate high similarity; approval delays possible |
| Pricing and reimbursement |
High prices under pressure due to regulatory scrutiny |
$38,000/vial retail; payers seek discounts |
| Competition from biosimilars |
Increased competition reduces market share and margins |
Biosimilar entrants by Sandoz and Teva |
What are the fundamental financial metrics to watch?
- Market penetration rates for biosimilars post-approval.
- Average selling price trends amid payer negotiations.
- Prescription volumes for infantile spasms and other indications.
- Legal and patent settlement costs influencing revenue.
- Cost of R&D for biosimilar development and pipeline refinement.
How does the current patent landscape shape investment potential?
Patent expiry in 2023 exposes Acthar Gel to biosimilar launches. Biosimilar entrants could capture significant market share within 1–2 years of approval, eroding revenues. Historical biosimilar market entry timelines suggest initial slow uptake but significant long-term price reductions.
Key biosimilar approval milestones:
- Sandoz's biosimilar application submitted in late 2022; approval expected within 12–18 months.
- Teva's biosimilar in late-stage development; timeline uncertain.
Patent litigation delays remain a significant risk, with potential for legal battles extending market exclusivity.
What are the fundamentals for long-term investment?
- Market size stability: While growth exists, it is limited by high-reimbursement prices and biosimilar competition.
- Pipeline viability: No significant innovation in ACTH formulations; biosimilars dominate future growth prospects.
- Regulatory climate: Favorable biosimilar approval processes could accelerate competition; adverse policies could enhance exclusivity.
- Pricing power: High current prices are under pressure; margins may decline with biosimilar entry.
- Patent challenges: Ongoing litigation impacts timing and profitability.
Key Takeaways
- The ACTH market is mature, with limited growth prospects beyond biosimilar threats.
- Patent expiration in 2023 initiates a period of increased biosimilar competition.
- High drug prices face regulatory scrutiny, influencing future revenue.
- Investment hinges on biosimilar approval timelines, legal outcomes, and market acceptance.
- No significant pipeline developments or innovation mitigate long-term growth but could influence short-term valuation.
FAQs
1. How does biosimilar entry affect ACTH product revenues?
Biosimilars typically reduce prices and share of sales, impacting revenue streams. Initial market penetration is slow, but long-term effects can be substantial, with price reductions of 20–40% expected within 2–3 years post-approval.
2. What regulatory hurdles exist for biosimilar ACTH products?
Biosimilars must demonstrate high similarity in structure, function, and immunogenicity. Variability in the complex protein formulation complicates approval, possibly causing delays or rejections.
3. Is there scope for innovation in ACTH formulations?
Current efforts focus primarily on biosimilars. No significant pipeline or novel formulations are in late-stage development, limiting innovation-driven growth.
4. How might government policy influence this market?
Policy favors biosimilar penetration and cost containment. Initiatives to promote biosimilar adoption and price regulation could further compress margins.
5. What are the primary risks for investors in ACTH-related drugs?
Patent litigation, regulatory delays for biosimilars, market acceptance issues for biosimilars, and policy-driven price controls present key risks.
Citations
[1] IQVIA, 2021. "Pharmaceutical Market Data."
[2] FDA, 2023. "Biologics License Applications and Approvals."
[3] Sandoz, 2022. "Biosimilar Application Submission."
[4] Teva Pharmaceutical Industries, 2022. "Pipeline Update on Biosimilar Development."
